Betamethasone dipropionate (topical): Difference between revisions
Jump to navigation
Jump to search
Adeel Jamil (talk | contribs) No edit summary |
Adeel Jamil (talk | contribs) No edit summary |
||
| Line 15: | Line 15: | ||
<!--FDA-Labeled Indications and Dosage (Adult)--> | <!--FDA-Labeled Indications and Dosage (Adult)--> | ||
|fdaLIADAdult=* Betamethasone dipropionate Cream, USP 0.05% (Augmented) is a high-potency corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive [[dermatoses]] in patients 13 years and older. | |fdaLIADAdult=* Betamethasone dipropionate Cream, USP 0.05% (Augmented) is a [[corticosteroid|high-potency corticosteroid]] indicated for relief of the [[inflammatory]] and [[pruritic]] manifestations of corticosteroid-responsive [[dermatoses]] in patients 13 years and older. | ||
=====Dosing Information===== | =====Dosing Information===== | ||
| Line 32: | Line 32: | ||
* General: | * General: | ||
:* Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. | :* Systemic absorption of topical corticosteroids has produced reversible [[HPA axis|HPA axis suppression]], manifestations of [[Cushing’s syndrome]], [[hyperglycemia]], and [[glucosuria]] in some patients. | ||
:* Conditions which augment systemic absorption include the application of the more potent corticosteroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Use of more than one corticosteroid-containing product at the same time may increase total systemic glucocorticoid exposure. | :* Conditions which augment systemic absorption include the application of the more [[corticosteroids|potent corticosteroids]], use over large surface areas, prolonged use, and the addition of occlusive dressings. Use of more than one [[corticosteroid]]-containing product at the same time may increase total systemic [[glucocorticoid]] exposure. | ||
:* Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. | :* Therefore, patients receiving a large dose of a potent topical [[steroid]] applied to a large surface area should be evaluated periodically for evidence of [[HPA axis|HPA axis suppression]] by using the urinary free [[cortisol]] and [[ACTH|ACTH stimulation tests]]. If [[HPA axis|HPA axis suppression]] is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent [[steroid]]. | ||
:* Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. In an open-label pediatric study of 60 evaluable patients, of the 19 who showed evidence of suppression, 4 patients were tested 2 weeks after discontinuation of Betamethasone Dipropionate Cream, USP 0.05% (Augmented), and 3 of the 4 (75%) had complete recovery of HPA axis function. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. | :* Recovery of [[HPA axis|HPA axis function]] is generally prompt and complete upon discontinuation of the drug. In an open-label pediatric study of 60 evaluable patients, of the 19 who showed evidence of suppression, 4 patients were tested 2 weeks after discontinuation of Betamethasone Dipropionate Cream, USP 0.05% (Augmented), and 3 of the 4 (75%) had complete recovery of HPA axis function. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental [[corticosteroids|systemic corticosteroids]]. | ||
:* Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. | :* Children may absorb proportionally larger amounts of [[corticosteroids|topical corticosteroids]] and thus be more susceptible to [[toxicity|systemic toxicity]]. | ||
:* If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. | :* If [[irritation]] develops, [[corticosteroids|topical corticosteroids]] should be discontinued and appropriate therapy instituted. | ||
:* In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled. | :* In the presence of [[dermatitis|dermatological infections]], the use of an appropriate [[antifungal]] or [[antibiotic|antibacterial agent]] should be instituted. If a favorable response does not occur promptly, the [[corticosteroid]] should be discontinued until the infection has been adequately controlled. | ||
|clinicalTrials=* The only local adverse reaction reported to be possibly or probably related to treatment with Betamethasone Dipropionate Cream, USP 0.05% (Augmented) during adult controlled clinical studies was stinging. It occurred in 1 patient, 0.4%, of the 242 patients or subjects involved in the studies. | |clinicalTrials=* The only local adverse reaction reported to be possibly or probably related to treatment with Betamethasone Dipropionate Cream, USP 0.05% (Augmented) during adult controlled [[clinical studies]] was stinging. It occurred in 1 patient, 0.4%, of the 242 patients or subjects involved in the studies. | ||
* Adverse reactions reported to be possibly or probably related to treatment with Betamethasone Dipropionate Cream, USP 0.05% (Augmented) during a pediatric clinical study include signs of skin atrophy (telangiectasia, bruising, shininess). | * Adverse reactions reported to be possibly or probably related to treatment with Betamethasone Dipropionate Cream, USP 0.05% (Augmented) during a [[pediatric]] [[clinical study]] include signs of [[atrophy|skin atrophy]] ([[telangiectasia]], [[bruising]], shininess). [[atrophy|skin atrophy]] occurred in 7 of 67 (10%) patients, involving all age groups from 3 months – 12 years of age. | ||
* The following local adverse reactions are reported infrequently when topical corticosteroids are used as recommended. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria. | * The following local adverse reactions are reported infrequently when [[corticosteroids|topical corticosteroids]] are used as recommended. These reactions are listed in an approximate decreasing order of occurrence: [[burning]], [[itching]], [[irritation]], [[dryness]], [[folliculitis]], [[hypertrichosis]], [[acneiform eruptions]], [[hypopigmentation]], [[perioral dermatitis]], [[allergic contact dermatitis]], [[maceration|maceration of the skin]], [[dermatitis|secondary infection]], [[atrophy | ||
|skin atrophy]], [[striae]], [[miliaria]]. | |||
* Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. | * Systemic absorption of [[corticosteroids|topical corticosteroids]] has produced [[HPA axis|reversible hypothalamic-pituitary-adrenal (HPA) axis suppression]], manifestations of [[Cushing’s syndrome]], [[hyperglycemia]], and [[glucosuria]] in some patients. | ||
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of Betamethasone dipropionate in the drug label. | |postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of Betamethasone dipropionate in the drug label. | ||
|drugInteractions=There is limited information regarding <i>Drug Interactions</i> of Betamethasone dipropionate in the drug label. | |drugInteractions=There is limited information regarding <i>Drug Interactions</i> of Betamethasone dipropionate in the drug label. | ||
|FDAPregCat=C | |FDAPregCat=C | ||
|useInPregnancyFDA | |useInPregnancyFDA=====Teratogenic effects===== | ||
* Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. | * [[Corticosteroids]] are generally [[teratogenic]] in laboratory animals when administered systemically at relatively low dosage levels. | ||
* Betamethasone dipropionate has been shown to be teratogenic in rabbits when given by the intramuscular route at doses of 0.05 mg/kg. This dose is approximately 0.2- fold the maximum human dose based on a mg/m2 comparison. The abnormalities observed included umbilical hernias, cephalocele and cleft | * Betamethasone dipropionate has been shown to be [[teratogenic]] in rabbits when given by the intramuscular route at doses of 0.05 mg/kg. This dose is approximately 0.2- fold the maximum human dose based on a mg/m2 comparison. The abnormalities observed included umbilical hernias, [[cephalocele]] and [[cleft palate]]s. | ||
* Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on | * Some [[corticosteroids]] have been shown to be [[teratogenic]] after [[dermal]] application in laboratory animals. There are no adequate and well-controlled studies in [[pregnant]] women on ter[[a]]togenic effects from topically applied [[corticosteroids]]. Therefore, [[corticosteroid|topical corticosteroids]] should be used during [[pregnancy]] only if the potential benefit justifies the potential risk to the [[fetus]]. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. | ||
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category''' | |useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category''' | ||
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Betamethasone dipropionate in women who are pregnant. | There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Betamethasone dipropionate in women who are pregnant. | ||
|useInLaborDelivery=There is no FDA guidance on use of Betamethasone dipropionate during labor and delivery. | |useInLaborDelivery=There is no FDA guidance on use of Betamethasone dipropionate during labor and delivery. | ||
|useInNursing=* It is not known whether topical administration of corticosteroids can result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. | |useInNursing=* It is not known whether topical administration of corticosteroids can result in sufficient systemic absorption to produce detectable quantities in [[breast milk]]. Systemically administered [[corticosteroids]] are secreted into [[breast milk]] in quantities not likely to have a deleterious effect on the [[infant]]. Nevertheless, a decision should be made whether to discontinue [[nursing]] or to discontinue the drug, taking into account the importance of the drug to the mother. | ||
|useInPed=* Use of Betamethasone Dipropionate Cream, USP 0.05% (Augmented) in pediatric patients 12 years of age and younger is not recommended. | |useInPed=* Use of Betamethasone Dipropionate Cream, USP 0.05% (Augmented) in pediatric patients 12 years of age and younger is not recommended. | ||
* In an open-label study, 19 of 60 (32%) evaluable pediatric patients (aged 3 months – 12 years old) using Betamethasone Dipropionate Cream, USP 0.05% (Augmented) for treatment of atopic dermatitis demonstrated HPA axis suppression. The proportion of patients with adrenal suppression in this study was progressively greater, the younger the age group. | * In an open-label study, 19 of 60 (32%) evaluable pediatric patients (aged 3 months – 12 years old) using Betamethasone Dipropionate Cream, USP 0.05% (Augmented) for treatment of [[atopic dermatitis]] demonstrated [[HPA axis|HPA axis suppression]]. The proportion of patients with adrenal suppression in this study was progressively greater, the younger the age group. | ||
* Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio. The study described above supports this premise, as adrenal suppression in 9-12 year olds, 6-8 year olds, 2-5 year olds, and 3 months – 1 year old was 17%, 32%, 38%, and 50% respectively. | * [[Pediatric]] patients may demonstrate greater susceptibility to [[HAP axis|topical corticosteroid-induced HPA axis suppression]] and [Cushing’s syndrome]] than mature patients because of a larger [[skin]] surface area to body weight ratio. The study described above supports this premise, as adrenal suppression in 9-12 year olds, 6-8 year olds, 2-5 year olds, and 3 months – 1 year old was 17%, 32%, 38%, and 50% respectively. | ||
* Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Chronic corticosteroid therapy may interfere with the growth and development of children. | * [[HPA axis|Hypothalamic-pituitary-adrenal (HPA) axis suppression]], [[Cushing’s syndrome]], and [[intracranial hypertension]] have been reported in children receiving [[corticosteroid|topical corticosteroids]]. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma [[cortisol|cortisol levels]], and absence of response to [[ACTH|ACTH stimulation]]. Manifestations of [[intracranial hypertension]] include [[fontanelles|bulging fontanelles]], [[headaches]], and [[papilledema|bilateral papilledema]]. [[corticosteroid|Chronic corticosteroid therapy]] may interfere with the growth and development of children. | ||
|useInGeri=* Clinical studies of Betamethasone Dipropionate Cream, USP 0.05% (Augmented) included 104 subjects who were 65 years of age and over and 8 subjects who were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. However, greater sensitivity of some older individuals cannot be ruled out. | |useInGeri=* Clinical studies of Betamethasone Dipropionate Cream, USP 0.05% (Augmented) included 104 subjects who were 65 years of age and over and 8 subjects who were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. However, greater sensitivity of some older individuals cannot be ruled out. | ||
|useInGender=There is no FDA guidance on the use of Betamethasone dipropionate with respect to specific gender populations. | |useInGender=There is no FDA guidance on the use of Betamethasone dipropionate with respect to specific gender populations. | ||
| Line 136: | Line 137: | ||
| synonyms = Betamethasone-17,21-dipropionate | | synonyms = Betamethasone-17,21-dipropionate | ||
}} | }} | ||
|mechAction=* The corticosteroids are a class of compounds comprising steroid hormones secreted by the adrenal cortex and their synthetic analogs. In pharmacologic doses, corticosteroids are used primarily for their anti-inflammatory and/or immunosuppressive effects. | |mechAction=* The [[corticosteroids]] are a class of compounds comprising [[steroid hormones]] secreted by the [[adrenal cortex]] and their synthetic analogs. In [[pharmacologic]] doses, [[corticosteroids]] are used primarily for their [[anti-inflammatory]] and/or [[immunosuppressive]] effects. | ||
* Topical corticosteroids, such as betamethasone dipropionate, are effective in the treatment of corticosteroid-responsive dermatoses primarily because of their anti-inflammatory, antipruritic, and vasoconstrictive actions. However, while the physiologic, pharmacologic, and clinical effects of the corticosteroids are well known, the exact mechanisms of their actions in each disease are uncertain. Betamethasone dipropionate, a corticosteroid, has been shown to have topical (dermatologic) and systemic pharmacologic and metabolic effects characteristic of this class of drugs. | * [[corticosteroids|Topical corticosteroids]], such as betamethasone dipropionate, are effective in the treatment of [[skin disease|corticosteroid-responsive dermatoses]] primarily because of their [[anti-inflammatory]], [[antipruritic]], and [[vasoconstriction|vasoconstrictive actions]]. However, while the [[physiologic]], [[pharmacologic]], and clinical effects of the [[corticosteroids]] are well known, the exact mechanisms of their actions in each disease are uncertain. Betamethasone dipropionate, a [[corticosteroid]], has been shown to have topical ([[dermatologic]]) and systemic [[pharmacologic]] and [[metabolic]] effects characteristic of this class of drugs. | ||
|structure=* Betamethasone Dipropionate Cream, USP 0.05% (Augmented) contains betamethasone dipropionate, USP, a synthetic adrenocorticosteroid, for dermatologic use in an emollient base. Betamethasone, an analog of prednisolone, has a high degree of corticosteroid activity and a slight degree of mineralocorticoid activity. Betamethasone dipropionate is the 17, 21-dipropionate ester of betamethasone. | |structure=* Betamethasone Dipropionate Cream, USP 0.05% (Augmented) contains betamethasone dipropionate, USP, a synthetic [[adrenocorticosteroid]], for [[dermatologic]] use in an emollient base. Betamethasone, an analog of prednisolone, has a high degree of corticosteroid activity and a slight degree of mineralocorticoid activity. Betamethasone dipropionate is the 17, 21-dipropionate ester of betamethasone. | ||
* Chemically, betamethasone dipropionate is 9-fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate, with the empirical formula C28H37FO7, a molecular weight of 504.6, and the following structural formula: | * Chemically, betamethasone dipropionate is 9-fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate, with the empirical formula C28H37FO7, a molecular weight of 504.6, and the following structural formula: | ||
[[File:Betamethasone dipropionate structure.png|thumb|none| | [[File:Betamethasone dipropionate structure.png|thumb|none|400px|This image is provided by the National Library of Medicine.]] | ||
<!--Pharmacodynamics--> | <!--Pharmacodynamics--> | ||
|PD======Laboratory Tests===== | |PD======Laboratory Tests===== | ||
* The following tests may be helpful in evaluating HPA axis suppression: | * The following tests may be helpful in evaluating HPA axis suppression: | ||
:* Urinary free cortisol test | :* [[Urinary free cortisol test]] | ||
:* ACTH stimulation test | :* [[ACTH stimulation test]] | ||
|PK=* The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. | |PK=* The extent of [[percutaneous]] absorption of [[corticosteroid|topical corticosteroids]] is determined by many factors including the vehicle, the integrity of the [[skin|epidermal barrier]], and the use of [[dressings|occlusive dressings]]. | ||
* Topical corticosteroids can be absorbed through normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. | * Topical corticosteroids can be absorbed through normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. | ||
| Line 216: | Line 217: | ||
}} | }} | ||
<!--Pill Image--> | <!--Pill Image--> | ||
<!--Label Display Image--> | <!--Label Display Image--> | ||
<!--Category--> | <!--Category--> | ||
[[Category:Drug]] | [[Category:Drug]] | ||
Revision as of 19:44, 10 March 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Adeel Jamil, M.D. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Betamethasone dipropionate (topical) is a Adrenal glucocorticoid, endocrine-metabolic agent that is FDA approved for the treatment of and relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Common adverse reactions include hypertension, atrophic condition of skin, folliculitis, pruritus of skin, stinging of skin, depression, euphoria..
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
- Betamethasone dipropionate Cream, USP 0.05% (Augmented) is a high-potency corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years and older.
Dosing Information
- Apply a thin film of Betamethasone Dipropionate Cream, USP 0.05% (Augmented) to the affected skin areas once or twice daily. Treatment with betamethasone dipropionate cream, USP 0.05% (augmented) should be limited to 50 g per week.
- Betamethasone Dipropionate Cream, USP 0.05% (Augmented) is not to be used with occlusive dressings.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Betamethasone dipropionate in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Betamethasone dipropionate in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding FDA-Labeled Use of Betamethasone dipropionate in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Betamethasone dipropionate in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Betamethasone dipropionate in pediatric patients.
Contraindications
- Betamethasone Dipropionate Cream, USP 0.05% (Augmented) is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation.
Warnings
PRECAUTIONS
- General:
- Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.
- Conditions which augment systemic absorption include the application of the more potent corticosteroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Use of more than one corticosteroid-containing product at the same time may increase total systemic glucocorticoid exposure.
- Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.
- Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. In an open-label pediatric study of 60 evaluable patients, of the 19 who showed evidence of suppression, 4 patients were tested 2 weeks after discontinuation of Betamethasone Dipropionate Cream, USP 0.05% (Augmented), and 3 of the 4 (75%) had complete recovery of HPA axis function. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.
- Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity.
- If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.
- In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
Adverse Reactions
Clinical Trials Experience
- The only local adverse reaction reported to be possibly or probably related to treatment with Betamethasone Dipropionate Cream, USP 0.05% (Augmented) during adult controlled clinical studies was stinging. It occurred in 1 patient, 0.4%, of the 242 patients or subjects involved in the studies.
- Adverse reactions reported to be possibly or probably related to treatment with Betamethasone Dipropionate Cream, USP 0.05% (Augmented) during a pediatric clinical study include signs of skin atrophy (telangiectasia, bruising, shininess). skin atrophy occurred in 7 of 67 (10%) patients, involving all age groups from 3 months – 12 years of age.
- The following local adverse reactions are reported infrequently when topical corticosteroids are used as recommended. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, [[atrophy
|skin atrophy]], striae, miliaria.
- Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Betamethasone dipropionate in the drug label.
Drug Interactions
There is limited information regarding Drug Interactions of Betamethasone dipropionate in the drug label.
Use in Specific Populations
Pregnancy
Teratogenic effects=
- Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels.
- Betamethasone dipropionate has been shown to be teratogenic in rabbits when given by the intramuscular route at doses of 0.05 mg/kg. This dose is approximately 0.2- fold the maximum human dose based on a mg/m2 comparison. The abnormalities observed included umbilical hernias, cephalocele and cleft palates.
- Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Betamethasone dipropionate in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Betamethasone dipropionate during labor and delivery.
Nursing Mothers
- It is not known whether topical administration of corticosteroids can result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Use
- Use of Betamethasone Dipropionate Cream, USP 0.05% (Augmented) in pediatric patients 12 years of age and younger is not recommended.
- In an open-label study, 19 of 60 (32%) evaluable pediatric patients (aged 3 months – 12 years old) using Betamethasone Dipropionate Cream, USP 0.05% (Augmented) for treatment of atopic dermatitis demonstrated HPA axis suppression. The proportion of patients with adrenal suppression in this study was progressively greater, the younger the age group.
- Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and [Cushing’s syndrome]] than mature patients because of a larger skin surface area to body weight ratio. The study described above supports this premise, as adrenal suppression in 9-12 year olds, 6-8 year olds, 2-5 year olds, and 3 months – 1 year old was 17%, 32%, 38%, and 50% respectively.
- Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Chronic corticosteroid therapy may interfere with the growth and development of children.
Geriatic Use
- Clinical studies of Betamethasone Dipropionate Cream, USP 0.05% (Augmented) included 104 subjects who were 65 years of age and over and 8 subjects who were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. However, greater sensitivity of some older individuals cannot be ruled out.
Gender
There is no FDA guidance on the use of Betamethasone dipropionate with respect to specific gender populations.
Race
There is no FDA guidance on the use of Betamethasone dipropionate with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Betamethasone dipropionate in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Betamethasone dipropionate in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Betamethasone dipropionate in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Betamethasone dipropionate in patients who are immunocompromised.
Administration and Monitoring
Administration
- Topical
Monitoring
There is limited information regarding IV Compatibility of Betamethasone dipropionate in the drug label.
IV Compatibility
There is limited information regarding IV Compatibility of Betamethasone dipropionate in the drug label.
Overdosage
- Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects.
Pharmacology
| |
Betamethasone dipropionate (topical)
| |
| Systematic (IUPAC) name | |
| [(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-(2-propanoyloxyacetyl)-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox |
| Mol. mass | 504.59 g/mol |
| SMILES | & |
| Synonyms | Betamethasone-17,21-dipropionate |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | topical |
Mechanism of Action
- The corticosteroids are a class of compounds comprising steroid hormones secreted by the adrenal cortex and their synthetic analogs. In pharmacologic doses, corticosteroids are used primarily for their anti-inflammatory and/or immunosuppressive effects.
- Topical corticosteroids, such as betamethasone dipropionate, are effective in the treatment of corticosteroid-responsive dermatoses primarily because of their anti-inflammatory, antipruritic, and vasoconstrictive actions. However, while the physiologic, pharmacologic, and clinical effects of the corticosteroids are well known, the exact mechanisms of their actions in each disease are uncertain. Betamethasone dipropionate, a corticosteroid, has been shown to have topical (dermatologic) and systemic pharmacologic and metabolic effects characteristic of this class of drugs.
Structure
- Betamethasone Dipropionate Cream, USP 0.05% (Augmented) contains betamethasone dipropionate, USP, a synthetic adrenocorticosteroid, for dermatologic use in an emollient base. Betamethasone, an analog of prednisolone, has a high degree of corticosteroid activity and a slight degree of mineralocorticoid activity. Betamethasone dipropionate is the 17, 21-dipropionate ester of betamethasone.
- Chemically, betamethasone dipropionate is 9-fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate, with the empirical formula C28H37FO7, a molecular weight of 504.6, and the following structural formula:
Pharmacodynamics
Laboratory Tests
- The following tests may be helpful in evaluating HPA axis suppression:
Pharmacokinetics
- The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.
- Topical corticosteroids can be absorbed through normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids.
- Once absorbed through the skin, topical corticosteroids enter pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees, are metabolized primarily in the liver and excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
- Betamethasone Dipropionate Cream, USP 0.05% (Augmented) was applied once daily at 7 grams per day for 1 week to diseased skin, in adult patients with psoriasis or atopic dermatitis, to study its effects on the hypothalamic-pituitary-adrenal (HPA) axis. The results suggested that the drug caused a slight lowering of adrenal corticosteroid secretion, although in no case did plasma cortisol levels go below the lower limit of the normal range.
- Sixty-seven pediatric patients ages 1 to 12 years, with atopic dermatitis, were enrolled in an open-label, hypothalamic-pituitary-adrenal (HPA) axis safety study. Betamethasone Dipropionate Cream, USP 0.05% (Augmented) was applied twice daily for 2 to 3 weeks over a mean body surface area of 58% (range 35% to 95%). In 19 of 60 (32%) evaluable patients, adrenal suppression was indicated by either a < 5 mcg/dL pre-stimulation cortisol, or a cosyntropin post-stimulation cortisol < 18 mcg/dL and/or an increase of < 7 mcg/dL from the baseline cortisol. Studies performed with Betamethasone Dipropionate Cream, USP 0.05% (Augmented) indicate that it is in the high range of potency as compared with other topical corticosteroids.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Betamethasone dipropionate in the drug label.
Clinical Studies
Carcinogenesis, Mutagenesis, Impairment of Fertility
- Long-term animal studies have not been performed to evaluate the carcinogenic potential of betamethasone dipropionate.
- Betamethasone was negative in the bacterial mutagenicity assay (Salmonella typhimurium and Escherichia coli), and in the mammalian cell mutagenicity assay (CHO/HGPRT). It was positive in the in-vitro human lymphocyte chromosome aberration assay, and equivocal in the in-vivo mouse bone marrow micronucleus assay. This pattern of response is similar to that of dexamethasone and hydrocortisone.
- Reproductive studies with betamethasone dipropionate carried out in rabbits at doses of 1.0 mg/kg by the intramuscular route and in mice up to 33 mg/kg by the intramuscular route indicated no impairment of fertility except for dose-related increases in fetal resorption rates in both species. These doses are approximately 5- and 38-fold the human dose based on a mg/m2 comparison, respectively.
How Supplied
Betamethasone Dipropionate Cream, USP 0.05% (Augmented) is supplied in:
NDC 0115-1472-52 15 g tubes
NDC 0115-1472-56 50 g tubes
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Manufactured by: TOLMAR Inc., Fort Collins, CO 80526 Distributed by: Global Pharmaceuticals Division of IMPAX Laboratories, Inc. Philadelphia, PA 19124 44945 Rev. 0 07/12
Storage
- Store between 2° and 30°C (36° and 86°F).
Images
Drug Images
{{#ask: Page Name::Betamethasone dipropionate (topical) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Betamethasone dipropionate (topical) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
- Patients using topical corticosteroids should receive the following information and instructions. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.
- This medication is to be used as directed by the physician and should not be used longer than the prescribed time period. It is for external use only. Avoid contact with the eyes.
- Patients should be advised not to use this medication for any disorder other than that for which it was prescribed.
- The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive.
- Patients should report any signs of local adverse reactions.
- Other corticosteroid-containing products should not be used with Betamethasone Dipropionate Cream, USP 0.05% (Augmented) without first talking to your physician.
Precautions with Alcohol
- Alcohol-Betamethasone dipropionate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- Celestone®
Look-Alike Drug Names
There is limited information regarding Betamethasone dipropionate (topical) Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
{{#subobject:
|Page Name=Betamethasone dipropionate (topical)
|Pill Name=No image.jpg
|Drug Name=
|Pill Ingred=|+sep=;
|Pill Imprint=
|Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
|Pill Color=|+sep=;
|Pill Shape=
|Pill Size (mm)=
|Pill Scoring=
|Pill Image=
|Drug Author=
|NDC=
}}
{{#subobject:
|Label Page=Betamethasone dipropionate (topical) |Label Name=Betamethasone dipropionate drug label01.png
}}
{{#subobject:
|Label Page=Betamethasone dipropionate (topical) |Label Name=Betamethasone dipropionate drug label02.png
}}
{{#subobject:
|Label Page=Betamethasone dipropionate (topical) |Label Name=Betamethasone dipropionate drug label03.png
}}
{{#subobject:
|Label Page=Betamethasone dipropionate (topical) |Label Name=Betamethasone dipropionate drug label04.png
}}